SINOMAB BIOSCIENCE LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.9 HKD | 0.00% |
|
-1.55% | +13.10% |
| Mar. 25 | SinoMab BioScience Limited Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Feb. 07 | SinoMab BioScience Limited Appoints Shanchun Wang as an Executive Director | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Capitalization 1 | 3,183 | 3,896 | 2,345 | 1,654 |
| Enterprise Value (EV) 1 | 2,030 | 3,077 | 2,031 | 1,589 |
| P/E ratio | -9.58 x | -31.8 x | -8.04 x | -5.58 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | 305,310,671 x | 87,965,706 x | 410,312,471 x |
| EV / Revenue | - | 241,175,561 x | 76,183,773 x | 394,141,340 x |
| EV / EBITDA | -8.76 x | -19.4 x | -6.85 x | -6.51 x |
| EV / FCF | -24,150,195 x | -14,357,530 x | -7,442,427 x | -7,596,648 x |
| FCF Yield | -0% | -0% | -0% | -0% |
| Price to Book | 2.81 x | 3.95 x | 3.45 x | 3.25 x |
| Nbr of stocks (in thousands) | 1,006,240 | 1,006,240 | 1,006,240 | 1,034,920 |
| Reference price 2 | 3.164 | 3.872 | 2.330 | 1.599 |
| Announcement Date | 4/27/20 | 4/28/21 | 4/27/22 | 4/26/23 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | 12.76 | 26.66 | 4.032 |
| EBITDA 1 | -38.49 | -55.2 | -231.8 | -158.6 | -296.4 | -244.3 |
| EBIT 1 | -39.6 | -56.28 | -234 | -162.7 | -305.9 | -258.9 |
| Operating Margin | - | - | - | -1,274.7% | -1,147.38% | -6,421.8% |
| Earnings before Tax (EBT) 1 | -51.9 | -83.61 | -276.3 | -122.6 | -288.2 | -284.2 |
| Net income 1 | -47.97 | -83.61 | -276.3 | -122.6 | -288.2 | -284.2 |
| Net margin | - | - | - | -960.82% | -1,081.12% | -7,047.57% |
| EPS 2 | -0.0780 | -0.1156 | -0.3302 | -0.1218 | -0.2897 | -0.2865 |
| Free Cash Flow | - | -28.8 | -84.04 | -214.3 | -272.9 | -209.2 |
| FCF margin | - | - | - | -1,679.78% | -1,023.64% | -5,188.36% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 10/31/19 | 10/31/19 | 4/27/20 | 4/28/21 | 4/27/22 | 4/26/23 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 99 | 18.8 | - | - | - | - |
| Net Cash position 1 | - | - | 1,154 | 818 | 314 | 65.2 |
| Leverage (Debt/EBITDA) | -2.573 x | -0.3397 x | - | - | - | - |
| Free Cash Flow | - | -28.8 | -84 | -214 | -273 | -209 |
| ROE (net income / shareholders' equity) | - | 710% | -47.7% | -11.6% | -34.6% | -47.8% |
| ROA (Net income/ Total Assets) | - | -28.1% | -21.3% | -8.42% | -17.6% | -15.8% |
| Assets 1 | - | 297.7 | 1,297 | 1,455 | 1,637 | 1,800 |
| Book Value Per Share 2 | -0.0800 | 0.0400 | 1.120 | 0.9800 | 0.6800 | 0.4900 |
| Cash Flow per Share 2 | 0.1100 | 0.0600 | 1.190 | 0.8100 | 0.5600 | 0.3300 |
| Capex 1 | 0.82 | 2.75 | 42.3 | 76 | 198 | 113 |
| Capex / Sales | - | - | - | 595.26% | 743.64% | 2,796.4% |
| Announcement Date | 10/31/19 | 10/31/19 | 4/27/20 | 4/28/21 | 4/27/22 | 4/26/23 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +13.10% | 265M | |
| -4.47% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- 3681 Stock
- Financials SinoMab BioScience Limited
